1001907-69-2 Usage
General Description
6-Ethylpyridine-3-boronic acid is an organic compound that belongs to the class of boronic acids. It is a boronic acid derivative of pyridine, containing an ethyl group. This chemical is commonly used as a building block in organic synthesis, particularly in the formation of C-N and C-O bonds. It can also be used as a ligand in transition metal-catalyzed cross-coupling reactions. Additionally, 6-Ethylpyridine-3-boronic acid has been investigated for its potential application in pharmaceuticals and agrochemicals due to its ability to form stable complexes with certain biological targets.
Check Digit Verification of cas no
The CAS Registry Mumber 1001907-69-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,1,9,0 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1001907-69:
(9*1)+(8*0)+(7*0)+(6*1)+(5*9)+(4*0)+(3*7)+(2*6)+(1*9)=102
102 % 10 = 2
So 1001907-69-2 is a valid CAS Registry Number.
InChI:InChI=1S/C7H10BNO2/c1-2-7-4-3-6(5-9-7)8(10)11/h3-5,10-11H,2H2,1H3
1001907-69-2Relevant articles and documents
APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF
-
Paragraph 00651; 00590, (2019/04/09)
Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.
BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120
-
Paragraph 0374; 0376, (2014/09/30)
The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.
